Oral anti-thrombotic medication management is crucial for patients post percutaneous coronary intervention(PCI).Identifying the optimal balance between ischemic and hemorrhagic risks has consistently been a highly concerning and urgent issue for clinicians.Given individual variations in risk and drug responses,guideline-recommended strategies may not suit all patients.Recent studies have explored tailored anti-thrombotic strategies for diverse groups,providing evidence for guideline revisions and offering multiple clinical treatment options.However,patient assessment,adjustment timing,and strategy formulation lack standardization and flexibility,necessitating professional consensus.This consensus statement,carefully crafted to meet clinical needs,emphasizes dynamic assessment and holistic management,prioritizing individual differences and patient adherence.It aims to offer practical,optimized anti-thrombotic regimens to improve patients' long-term outcomes.

With the aging of the population,the disease burden of heart valve disease in China has significantly increased.In recent years,the interventional treatment for heart valve disease has flourished,among which transcatheter aortic valve replacement(TAVR)has become the first-line treatment for elderly patients with aortic valve stenosis.China started relatively late in the field of interventional treatment for heart valve disease.The construction of heart valve centers helps to standardize the diagnosis and interventional treatment of heart valve disease in China and improve the management of prognosis for patients.Up to December 2024,a total of 453 centers have participated in the construction of heart valve centers,including 100 construction centers and 40 certification centers.The National Transcatheter Valve Therapeutics Registry(NTCVR)database has reported a total of 28 594 cases,with approximately 50％of Chinese TAVR cases recorded in NTCVR database.The construction of the heart valve centers has shown initial results,significantly optimizing the process of diagnosis and treatment of heart valve disease and improving the prognosis.At present,there are still many shortcomings in the construction of heart valve centers.For example,the follow-up rate of patients after discharge is low,and long-term management after discharge needs to be further improved.There is still a gap in some indicators between construction centers and certification centers,and the promotion of high-quality management of interventional treatment of heart valve disease in China is still a long way to go.

Objective To explore the safety and efficacy of applying Bivalirudin in complex high-risk and indicated patients(CHIP)undergoing percutaneous coronary intervention(PCI)while on extracorporeal membrane oxygenation(ECMO).This study will provide additional evidence for making informed decisions regarding anticoagulation therapy during ECMO.Methods A total of 83 CHIP who underwent VA-ECMO assisted PCI in the Heart Center of the First Hospital of Lanzhou University from March 2019 to December 2022 were retrospectively enrolled as the research objects.According to the use of anticoagulant drugs during ECMO support and PCI,they were divided into Bivalirudin group(40 cases)and heparin group(43 cases).The cost of anticoagulants,coefficient of variation of activated partial thromboplastin time(APTT),APTT compliance rate,bleeding events,thrombotic events,blood product transfusion,and net adverse clinical events(NACE)at 30 days after PCI were compared between the two groups to determine the safety and efficacy of Bivalirudin in CHIP undergoing ECMO assisted PCI.Results The proportion of previous PCI(25.00％vs.4.65％),fibrinogen level[(3.52±1.14)g/L vs.(2.92±1.28)g/L],CRUSADE score[(32.00±12.69)scores vs.(26.14±10.60)scores],anticoagulation cost[1 400.00(700.00,2 100.00)RMB vs.107.69(58.74,205.59)RMB]and compliance rate of APTT[(57.76±33.11)％vs.(31.44±27.63)％]in the Bivalirudin group were higher,while the coefficient of variation for APTT[10.64(7.72,21.11)vs.19.47(10.48,31.28)]was lower than those in the heparin group.The total bleeding events(25.00％vs.46.51％),Bleeding Academic Research Consortium(BARC)1-2 bleeding events(12.50％vs.32.56％),and total thrombotic events(12.50％vs.32.56％)of the Bivalirudin group was significantly lower compared with the heparin group.Kaplan-Meier curves showed that cumulative incidence of 30-days NACE was significantly lower in the Bivalirudin group than in the heparin group.The differences between the above two groups were statistically significant(Log-rank P＜0.001).Conclusions Compared with heparin,Bivalirudin has better safety and efficacy in CHIP undergoing PCI assisted by VA-ECMO.

Objective To compare the differences in clinical prognosis and safety between thoracic endovascular aortic repair(TEVAR)combined with bare metal stent(BMS)implantation therapy and TEVAR alone in patients with type B aortic dissection(TBAD)after 6 months.Methods The clinical and imaging data of patients diagnosed with TBAD and treated with TEVAR or TEVAR combined with BMS implantation in Nanyang Central Hospital from March 2023 to March 2024 were retrospectively collected.The patients were divided into TEVAR group and TEVAR+BMS group according to different treatment methods.The aortic remodeling indicators and postoperative complications at discharge and 6 months after surgery were compared between the two groups.Results A total of 37 patients were included,including 20 patients in the TEVAR group and 17 patients in the TEVAR+BMS group.There were no statistically significant differences in baseline data between the two groups(all P＞0.05);at discharge and 6 months after surgery,the true lumen diameters and true lumen ratios of the abdominal aorta(proximal level of the celiac trunk and proximal level of the left renal artery)in the TEVAR+BMS group were better than those in the TEVAR group(all P＜0.05);the degree of thrombosis of the false lumen at 6 months after surgery was better in the TEVAR+BMS group than in the TEVAR group(P＜0.05);there was no statistically significant difference in postoperative complications between the two groups(P＞0.05).Conclusions TEVAR combined with BMS implantation therapy can significantly improve the aortic remodeling effect of patients with TBAD,without increasing the risk of postoperative complications and death caused by aortic-related factors.Bare stent implantation as an auxiliary treatment method for endovascular repair is a safe and effective optimized treatment plan.

Transcatheter electrosurgery has emerged as an innovative interventional technique for treating structural heart disease in recent years.This technology utilizes radiofrequency energy delivered through catheter systems to perform puncture,cutting,or ablation of cardiovascular tissues,providing new treatment options for patients with complex structural heart disease.The technique has evolved from simple valve perforation to sophisticated valve modifications,developing various innovative procedures to address key clinical challenges in interventional treatment.The basic principle involves using radiofrequency energy to heat and vaporize target tissues while minimizing damage to surrounding structures.This review comprehensively discusses the fundamental principles,technical characteristics,clinical applications,and future prospects of transcatheter electrosurgery.Current applications include recanalization of occlusive lesions,intracardiac chamber access,and tissue modification for structural interventions.While showing promising results in various complex cases,the technology still faces challenges such as the learning curve and the need for specialized equipment.As the field continues to develop,transcatheter electrosurgery is expected to play an increasingly important role in structural heart interventions,though more long-term data is needed to fully evaluate its safety and efficacy.

Patent foramen ovale(PFO)is a common congenital heart defect that has been linked to various conditions,including cryptogenic stroke,migraine with aura,and decompression sickness.With the rapid advancement of interventional cardiology,interventional treatment has become the preferred approach for PFO patients.Conventional PFO closure procedures predominantly use metallic disc occluders,which,despite their excellent surgical outcomes,come with unavoidable device-related complications.Consequently,there is an urgent need for a percutaneous PFO closure strategy that does not require the permanent implantation of an occluder,aligning with the"intervention without implantation,implantation without residue"green philosophy to address the limitations of traditional PFO occluders.Transcatheter PFO suturing represents a technique that better conforms to the anatomical and physiological requirements of PFO closure,capable of overcoming many of the device-related complications associated with conventional PFO closure,offering good safety and efficacy.This paper reviews the research advancements in transcatheter PFO suturing,aiming to provide novel perspectives for the clinical management of these conditions.

Medical therapy and surgical intervention are the two primary approaches for treating myocardial bridge.However,there remains controversy regarding the use of coronary artery bypass grafting(CABG)and myocardial bridge unroofing.Here,we report a case of myocardial infarction following CABG in a patient with a myocardial bridge.The patient was admitted to Lanzhou First Peopie's Hospital with persistent chest pain,chest tightness,and shortness of breath lasting 2 hours.Physical examination revealed no significant abnormalities.Electrocardiography(ECG)indicated extensive anterior wall myocardial infarction.Laboratory findings showed myoglobin levels of 140.1 ng/ml and troponin Ⅰ levels of 2.59 ng/ml,with no other significant abnormalities.The initial diagnosis was acute extensive anterior wall myocardial infarction.Emergency coronary angiography revealed a myocardial bridge in the mid-segment of the left anterior descending artery(LAD).Emergency CABG using the left internal mammary artery to the LAD was performed,leading to symptomatic improvement,and the patient was discharged in stable condition.However,the patient experienced a recurrent myocardial infarction seven years post-surgery and received secondary preventive medical therapy.The patient is currently under ongoing follow-up care.CABG is an effective treatment for myocardial bridge.However,based on the case reported in this study,we recommend careful evaluation of whether a patient may benefit from CABG.

End-stage dilated cardiomyopathy belongs to the irreversible cardiac decompensation stage,and neither drugs nor cardiac resynchronization therapy can improve the symptoms of heart failure in patients.Orthotopic heart transplantation is a surgical procedure that involves removing the diseased heart of the recipient and implanting the donor heart in its original position.With the advancements in surgical transplantation techniques and immunosuppressive therapy,it has become an effective treatment for end-stage heart disease.Coronary artery disease after heart transplantation is one of the issues that need attention after heart transplantation.This article reports a 68-year-old male who suffered from recurrent heart failure and ventricular tachycardia due to"dilated cardiomyopathy"and underwent allogeneic orthotopic heart transplantation 5 years ago.The patient underwent coronary angiography and intravascular ultrasound examination under local anesthesia.This case has certain guiding significance for studying the progression of coronary artery disease in heart transplant patients.

An implantable cardiac monitor(ICM)is a subcutaneous electronic device for recording and remotely transmitting electrocardiographic events.New-generation ICM,like the Reveal LINQ,have extended arrhythmia monitoring duration and improved diagnostic yield through miniaturization,large storage capacity,and easy implantation.They provide comprehensive monitoring data for cardiovascular disease diagnosis and treatment,optimize individualized treatment plans,and enhance patient prognosis.In recent years,research on ICM in cardiovascular fields has deepened,and their clinical application scope has expanded.They show significant advantages and unique value and are widely used in early cardiovascular disease diagnosis and prognostic management.In the future,ICM are expected to play a bigger role in boosting diagnostic and prognostic capabilities for cardiovascular disease patients,offering stronger support for early disease detection,accurate diagnosis,and effective management.

Objective To develop a deep learning model based on fundus retinal images to improve the detection rate of mild cognitive impairment(MCI)in patients with coronary heart disease,achieve early intervention and improve prognosis.Methods The study was a single-center cross-sectional study that retrospectively included patients diagnosed with coronary heart disease(CHD)by coronary angiography(≥50％ stenosis of at least one coronary vessel)from Beijing Anzhen Hospital between November 2021 and December 2022.The whole data set was randomly divided into the training set and the testing set according to the ratio of 8∶2 for model development.After that,the patient data of the same center from January 2023 to April 2023 were included in the time verification method to verify the model.The diagnostic criteria for MCI were MMSE＜27 or MoCA＜26.Four kinds of convolutional neural network(CNN)architectures were used to train fundus images,and a comprehensive vision model of MCI detection was established through model integration.The area under the curve(AUC),sensitivity and specificity of the receiver operating curve(ROC)were used to evaluate the performance of the AI model.Results We collected 5 880 eligible fundus images from 3 368 CHD patients.Based on the results of the MMSE scale,the algorithm was labeled,including 2 898 males and 527 MCI patients.The AUC of the deep learning model in the test group is 0.733(95％CI 0.688-0.778),and the sensitivity of the algorithm in the test group is 0.577(95％CI 0.528-0.625)by using the operating point with the maximum sum of sensitivity and specificity.With a specificity of 0.758(95％CI 0.714-0.802),corresponding to a validated AUC of 0.710(95％CI 0.601-0.818).Based on the results of the MoCA scale,the algorithm labels 2 437 males and 1 626 MCI patients.The AUC of the deep learning model in the test group was 0.702(95％CI 0.671-0.733).The operating point with the maximum sum of sensitivity and specificity was selected,and the sensitivity of the algorithm was 0.749(95％CI 0.719-0.778)and the specificity was 0.561(95％CI 0.527-0.595),corresponding to the AUC value of the verification group was 0.674(95％CI 0.622-0.726).Conclusions The deep learning algorithm model based on fundus images has good diagnostic performance,and may be used as a new non-invasive,convenient and rapid screening method for MCI in CHD population.